Compare
ANI Pharmaceuticals Inc vs Harmony Biosciences Holdings, Inc. vs Arrowhead Pharmaceuticals, Inc. vs Ionis Pharmaceuticals Inc
| Latest fiscal year | ANI Pharmaceuticals Inc ANIP | Harmony Biosciences Holdings, Inc. HRMY | Arrowhead Pharmaceuticals, Inc. ARWR | Ionis Pharmaceuticals Inc IONS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $883.37M | $868.45M | $829.45M | $943.71M |
| Revenue growth (YoY) | +43.8% | +21.5% | n/m | +33.8% |
| Gross margin | n/a | 77.2% | n/a | n/a |
| Operating margin | 12.6% | 24.0% | 11.9% | -40.4% |
| Net margin | 8.9% | 18.3% | 3.6% | -40.4% |
| Net income | $78.34M | $158.69M | $30.11M | -$381.39M |
| EPS (Diluted) | $3.32 | $2.71 | -$0.01 | -$2.38 |
| Operating cash flow | $185.22M | $348.20M | $179.55M | -$268.58M |
| Free cash flow | $171.39M | $347.89M | $156.89M | -$320.03M |
| Cash & equivalents | $285.58M | $752.50M | n/a | $372.26M |
| Total assets | $1.44B | $1.27B | $1.39B | $3.52B |
| Total liabilities | $899.65M | $401.41M | n/a | $3.03B |
| Shareholders' equity | $540.72M | $870.22M | $503.42M | $489.09M |
| Return on year-end equity | 14.5% | 18.2% | 6.0% | -78.0% |
| Shares outstanding | 22.49M | 57.73M | 135.70M | 163.30M |
Revenue, most recent five fiscal years
| Fiscal year | ANI Pharmaceuticals Inc | Harmony Biosciences Holdings, Inc. | Arrowhead Pharmaceuticals, Inc. | Ionis Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $883.37M Ended 2025-12-31 | $868.45M Ended 2025-12-31 | $829.45M Ended 2025-09-30 | $943.71M Ended 2025-12-31 |
| 1 year earlier | $614.38M Ended 2024-12-31 | $714.73M Ended 2024-12-31 | $3.55M Ended 2024-09-30 | $705.14M Ended 2024-12-31 |
| 2 years earlier | $486.82M Ended 2023-12-31 | $582.02M Ended 2023-12-31 | $240.74M Ended 2023-09-30 | $787.65M Ended 2023-12-31 |
| 3 years earlier | $316.38M Ended 2022-12-31 | $437.86M Ended 2022-12-31 | $243.23M Ended 2022-09-30 | $587.37M Ended 2022-12-31 |
| 4 years earlier | $216.14M Ended 2021-12-31 | $305.44M Ended 2021-12-31 | $138.29M Ended 2021-09-30 | $810.46M Ended 2021-12-31 |